China’s Landwind Diagnostics Maker Target Of Global Investors
This article was originally published in PharmAsia News
Executive Summary
A pair of global equity firms are eyeing China's Landwind as a possible investment target. Citi Venture Capital International already owns about 70 percent of the maker and distributor of diagnostic-imaging equipment. But the U.S. equity firms are among about 20 private-equity firms, including many in China, considering making bids for Landwind. (Click here for more